What is Scotiabank’s Estimate for Albemarle FY2026 Earnings?

Albemarle Corporation (NYSE:ALB – Free Report) – Research analysts at Scotiabank reduced their FY2026 earnings per share (EPS) estimates for shares of Albemarle in a report released on Monday, November 9th. Scotiabank analyst B. Isaacson now expects that the specialty chemicals company will post earnings of $10.36 per share for the year, down from their previous estimate of $11.64. Scotiabank has a “Sector Outperform” rating and a $165.00 price objective on the stock. The consensus estimate for Albemarle’s current full-year earnings is $10.70 per share. Scotiabank also issued estimates for Albemarle’s FY2027 earnings at $9.98 EPS.

ALB has been the topic of several other reports. UBS Group decreased their target price on shares of Albemarle from $150.00 to $137.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen downgraded shares of Albemarle from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Truist Financial reiterated a “buy” rating and issued a $170.00 price objective (down from $185.00) on shares of Albemarle in a research note on Friday, November 6th. Royal Bank Of Canada decreased their price objective on shares of Albemarle from $129.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, November 6th. Finally, Mizuho upgraded shares of Albemarle from a “neutral” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Wednesday, October 14th. Fifteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Albemarle presently has a consensus rating of “Moderate Buy” and an average target price of $174.05.

Check Out Our Latest Research Report on Albemarle

Albemarle Trading Down 1.1%

NYSE:ALB opened at $94.91 on Wednesday. The stock has a fifty day moving average price of $104.38 and a two-hundred day moving average price of $146.06. The stock has a market capitalization of $11.20 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 0.60 and a beta of 1.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 2.34. Albemarle has a 1 year low of $89.77 and a 1 year high of $221.00.

Albemarle (NYSE:ALB – Get Free Report) last issued its earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.52 billion. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.19) EPS.

Albemarle Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, December 18th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.64 annualized dividend and a yield of 1.7%. Albemarle’s dividend payout ratio is 39.61%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALB. Ingalls & Snyder LLC boosted its position in shares of Albemarle by 52.5% in the 3rd quarter. Ingalls & Snyder LLC now owns 3,031 shares of the specialty chemicals company’s stock worth $321,000 after buying an additional 1,043 shares in the last quarter. AlphaGrep UK Ltd grew its stake in Albemarle by 133.0% in the 3rd quarter. AlphaGrep UK Ltd now owns 4,431 shares of the specialty chemicals company’s stock valued at $469,000 after acquiring an additional 2,529 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in Albemarle by 212.3% during the 3rd quarter. Benjamin Edwards Inc. now owns 17,422 shares of the specialty chemicals company’s stock valued at $1,843,000 after acquiring an additional 11,843 shares in the last quarter. First Trust Advisors LP increased its holdings in Albemarle by 18.3% during the 3rd quarter. First Trust Advisors LP now owns 295,431 shares of the specialty chemicals company’s stock valued at $31,251,000 after acquiring an additional 45,746 shares in the last quarter. Finally, BNP Paribas purchased a new position in Albemarle during the 3rd quarter valued at about $7,367,000. Hedge funds and other institutional investors own 92.87% of the company’s stock.

Albemarle Company Profile

(Get Free Report)

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.

Featured Articles

Earnings History and Estimates for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.